クロダ　ハジメ   KURODA Hajime   黒田　一    所属   医学部 医学科（附属足立医療センター）    職種   教授
論文種別	原著
言語種別	英語
査読の有無	査読あり
表題	Clinical and Diagnostic Utility of Genomic Profiling for Digestive Cancers: Real-World Evidence from Japan.
掲載誌名	正式名：Cancers 略　 称：Cancers (Basel) ISSNコード：20726694/20726694
掲載区分	国外
巻・号・頁	16(8),pp.1504
著者・共著者	Ishikawa Marin†, Nakamura Kohei, Kawano Ryutaro, Hayashi Hideyuki, Ikeda Tatsuru, Saito Makoto, Niida Yo, Sasaki Jiichiro, Okuda Hiroyuki, Ishihara Satoshi, Yamaguchi Masatoshi, Shimada Hideaki, Isobe Takeshi, Yuza Yuki, Yoshimura Akinobu, Kuroda Hajime, Yukisawa Seigo, Aoki Takuya, Takeshita Kei, Ueno Shinichi, Nakazawa Junichi, Sunakawa Yu, Nohara Sachio, Okada Chihiro, Nishimiya Ko, Tanishima Shigeki, Nishihara Hiroshi*
発行年月	2024/04
概要	The usefulness of comprehensive genomic profiling (CGP) in the Japanese healthcare insurance system remains underexplored. Therefore, this large-scale study aimed to determine the usefulness of CGP in diagnosing digestive cancers. Patients with various cancer types recruited between March 2020 and October 2022 underwent the FoundationOne® CDx assay at the Keio PleSSision Group (19 hospitals in Japan). A scoring system was developed to identify potentially actionable genomic alterations of biological significance and actionable genomic alterations. The detection rates for potentially actionable genomic alterations, actionable genomic alterations, and alterations equivalent to companion diagnosis (CDx), as well as the signaling pathways associated with these alterations in each digestive cancer, were analyzed. Among the 1587 patients, 547 had digestive cancer. The detection rates of potentially actionable genomic alterations, actionable genomic alterations, and alterations equivalent to CDx were 99.5%, 62.5%, and 11.5%, respectively. APC, KRAS, and CDKN2A alterations were frequently observed in colorectal, pancreatic, and biliary cancers, respectively. Most digestive cancers, except esophageal cancer, were adenocarcinomas. Thus, the classification flowchart for digestive adenocarcinomas proposed in this study may facilitate precise diagnosis. CGP has clinical and diagnostic utility in digestive cancers.
DOI	10.3390/cancers16081504
PMID	38672586